Claudio Bonometti, MD
Clinical Cardiac Electrophysiology · Las Vegas, NVNPI 1053326728
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.7%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Biosense Webster, Inc. at 34.7% of the total. Reporting peaked in 2019 at $35,552 and has fallen 76.4% since, to $8,397 in 2025. Among clinical cardiac electrophysiology clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 919 payments — averaging $96.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$31K
- Johnson & Johnson$25K
- Abbott$8K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
- Biotronik Inc.$6K
- Medtronic$3K
- plus $9K from 29 others
Across 52 payments — averaging $261.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biotronik Inc.$11K
- Cvrx, Inc.$2K
- Boston Scientific$945
What the payments were for
- Consulting fees$3,1003%
- Speaking & faculty fees$31,50035%
- Travel & lodging$1,1661%
- Food & beverage$52,95360%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 364 | $30,824 |
| Johnson & Johnson | 56 | $25,084 |
| Abbott | 67 | $8,250 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $6,577 |
| Biotronik Inc. | 32 | $5,601 |
| Medtronic(2 entities) | 56 | $3,077 |
| Cardiofocus, Inc. | 18 | $1,342 |
| Merck | 33 | $945 |
| Amgen | 84 | $870 |
| Boston Scientific | 15 | $794 |
| Novartis | 41 | $707 |
| E.r. Squibb & Sons, L.L.C. | 26 | $659 |
| Cordis US CORP. | 5 | $561 |
| Acutus Medical, Inc. | 5 | $521 |
| ZOLL Respicardia, Inc. | 3 | $381 |
| Shockwave Medical, Inc | 5 | $357 |
| Bayer | 15 | $356 |
| Cardiva Medical, Inc. | 5 | $274 |
| Lexicon Pharmaceuticals, Inc. | 11 | $268 |
| Sanofi-aventis U.S. LLC | 14 | $245 |
| Bridgebio Pharma, Inc. | 5 | $239 |
| Alnylam Pharmaceuticals Inc. | 4 | $177 |
| Cvrx, Inc. | 1 | $137 |
| Novo Nordisk | 1 | $122 |
| Kestra Medical Technology Services, Inc. | 2 | $65 |
| Pfizer | 4 | $63 |
| Edwards Lifesciences | 3 | $59 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $53 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $24 |
| Elutia, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| AstraZeneca | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$24,507
- Carto 3$8,834
- Carto 3 System$8,005
- LifeVest$5,834
- Perclose ProGlide suture mediated closure system$2,765
- AVEIR$1,379
- Soundstar$1,041
- Micra$922
- CARDIOMEMS$852
- HeartLight System$787
- Edora$779
- Quadra Assura CRT Defibrillator$766
- VERQUVO$722
- VISITAG SURPOINT External Processing Unit$711
- BioMonitor$633
- NA$481
- remede System$381
- Acticor$379
- Solia$379
- Rivacor$379
How this compares
$88,750 in reported general payments places this provider in the 95th percentile of 20 clinical cardiac electrophysiology providers in Nevada.
See all clinical cardiac electrophysiology providers in Nevada →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 333 | $393,135 |
| EntrestoSacubitril/Valsartan | 173 | $277,551 |
| VerquvoVericiguat | 116 | $166,962 |
| MultaqDronedarone Hcl | 65 | $114,140 |
| Repatha SureclickEvolocumab | 100 | $94,220 |
| XareltoRivaroxaban | 65 | $89,284 |
| BrilintaTicagrelor | 35 | $26,591 |
| FarxigaDapagliflozin Propanediol | 17 | $20,145 |
| OzempicSemaglutide | 11 | $16,342 |
| LivaloPitavastatin Calcium | 13 | $10,764 |
| Rosuvastatin Calcium | 448 | $5,344 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 17 | $4,208 |
| Nebivolol Hcl | 47 | $3,123 |
| Carvedilol | 270 | $2,235 |
| Flecainide Acetate | 20 | $1,830 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $63 | $393,135333 claims |
| NovartisEntresto | $707 | $277,551173 claims |
| MerckVerquvo | $945 | $166,962116 claims |
| Sanofi-aventis U.S. LLCMultaq | $245 | $114,14065 claims |
| Johnson & JohnsonXarelto | $25,084 | $89,28465 claims |
| AstraZenecaBrilinta, Farxiga | $15 | $46,73652 claims |
| Novo NordiskOzempic | $122 | $16,34211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 clinical cardiac electrophysiology providers in Nevada.
Other clinical cardiac electrophysiology in Las Vegas
- Erik SirulnickLas Vegas$44K
- Niuton KoideLas Vegas$34K
- David NavratilLas Vegas$29K
- Dhiraj NarulaLas Vegas$14K
- Santosh RaneLas Vegas$11K
- Gaston VergaraLas Vegas$11K
- Subhasree PanchangamLas Vegas$4K
- Khawaja BaigLas Vegas$3K
- Daejoon AnhHenderson$33K
- Jeffrey TurnerCarson City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.